RBC Life Sciences Begins Selling Products in Burgeoning Taiwan Market
IRVING, Texas, March 24 /PRNewswire-FirstCall/ -- RBC Life Sciences (OTC Bulletin Board: RBCL) — RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, announced today that it has begun selling selected nutritional supplements in Taiwan utilizing the Not for Resale (NFR) model.
"Taiwan is an exciting market and is our entry to expanding sales throughout Asia," said RBC Life Sciences President and CEO John W. Price. "By tradition, the Taiwanese are well aware of the role proper nutrition plays in optimal health. In fact, an overwhelming majority of Taiwanese consume nutritional supplements as part of their daily diet. The proprietary antioxidants and immune support products we're offering are perfect for this market."
RBC Life Sciences initially is offering only their flagship products through a dedicated Not For Resale Program, with additional products to be added later. Consumers may purchase products through the NFR Program by clicking on the "NFR Website" link at http://www.rbclife.com.
The NFR Program allows consumers in Taiwan to sign up as customers, purchase products, refer others to the program and receive commissions. The NFR Program also allows RBC Life Sciences' independent Associates in the United States and Canada to build their domestic-based businesses in Taiwan.
One of the five products currently offered through the NFR Program is NeuroBright, a patent-pending botanical and antioxidant product formulated to assist brain health. A recent laboratory trial showed that test subjects' learning and memory improved nearly 50 percent after consuming NeuroBright.
About RBC Life Sciences
Through U.S. and Canadian subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. MPM Medical, the company's medical products subsidiary, develops and markets proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE RBC Life Sciences, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article